Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

425 ARTÍCULOS , VIENDO DEL 31 AL 45

A pilot study on the effect of lactoferrin on Alzheimer's disease pathological sequelae: Impact of the p-Akt/PTEN pathway

Mohamed WA, Salama RM, Schaalan MF.

Biomed Pharmacother. 2019 Mar;111:714-723. doi: 10.1016/j.biopha.2018.12.118. Epub 2019 Jan 3.

Multidisciplinary approaches for targeting the secretase protein family as a therapeutic route for Alzheimer's disease

Schaduangrat N, Prachayasittikul V, Choomwattana S, Wongchitrat P, Phopin K, Suwanjang W, Malik AA, Vincent B, Nantasenamat C.

Med Res Rev. 2019 Sep;39(5):1730-1778. doi: 10.1002/med.21563. Epub 2019 Jan 9.

Treating Alzheimer's disease by targeting iron

Nikseresht S, Bush AI, Ayton S.

Br J Pharmacol. 2019 Sep;176(18):3622-3635. doi: 10.1111/bph.14567. Epub 2019 Feb 11.

Recent therapeutic strategies targeting beta amyloid and tauopathies in Alzheimer's disease

Madav Y, Wairkar S, Prabhakar B.

Brain Res Bull. 2019 Mar;146:171-184. doi: 10.1016/j.brainresbull.2019.01.004. Epub 2019 Jan 8.

Amyloid-β immunotherapy for alzheimer disease: Is it now a long shot?

Panza F, Lozupone M, Seripa D, Imbimbo BP.

Ann Neurol. 2019 Mar;85(3):303-315. doi: 10.1002/ana.25410. Epub 2019 Jan 28.

Don't forget astrocytes when targeting Alzheimer's disease

Sadick JS, Liddelow SA.

Br J Pharmacol. 2019 Sep;176(18):3585-3598. doi: 10.1111/bph.14568. Epub 2019 Feb 19.

Procyanidins and Alzheimer's Disease

Zhao S, Zhang L, Yang C, Li Z, Rong S.

Mol Neurobiol. 2019 Aug;56(8):5556-5567. doi: 10.1007/s12035-019-1469-6. Epub 2019 Jan 16.

The Promises and Challenges of Erythropoietin for Treatment of Alzheimer's Disease

Sun J, Martin JM, Vanderpoel V, Sumbria RK.

Neuromolecular Med. 2019 Mar;21(1):12-24. doi: 10.1007/s12017-019-08524-y. Epub 2019 Jan 17.

A short perspective on the long road to effective treatments for Alzheimer's disease

Reynolds DS.

Br J Pharmacol. 2019 Sep;176(18):3636-3648. doi: 10.1111/bph.14581. Epub 2019 Mar 1.

Why Microtubules Should Be Considered as One of the Supplementary Targets for Designing Neurotherapeutics

Das G, Ghosh S.

ACS Chem Neurosci. 2019 Mar 20;10(3):1118-1120. doi: 10.1021/acschemneuro.9b00002. Epub 2019 Jan 18.

Metal Toxicity Links to Alzheimer's Disease and Neuroinflammation

Huat TJ, Camats-Perna J, Newcombe EA, Valmas N, Kitazawa M, Medeiros R.

J Mol Biol. 2019 Apr 19;431(9):1843-1868. doi: 10.1016/j.jmb.2019.01.018. Epub 2019 Jan 18.

Nicotinamide Mononucleotide: Exploration of Diverse Therapeutic Applications of a Potential Molecule

Poddar SK, Sifat AE, Haque S, Nahid NA, Chowdhury S, Mehedi I.

Biomolecules. 2019 Jan 21;9(1):34. doi: 10.3390/biom9010034.

Recent Expansions on Cellular Models to Uncover the Scientific Barriers Towards Drug Development for Alzheimer's Disease

Dubey SK, Ram MS, Krishna KV, Saha RN, Singhvi G, Agrawal M, Ajazuddin, Saraf S, Saraf S, Alexander A.

Cell Mol Neurobiol. 2019 Mar;39(2):181-209. doi: 10.1007/s10571-019-00653-z. Epub 2019 Jan 23.

Rapamycin and Alzheimer's disease: Time for a clinical trial?

Kaeberlein M, Galvan V.

Sci Transl Med. 2019 Jan 23;11(476):eaar4289. doi: 10.1126/scitranslmed.aar4289.

Mitochondrial dysfunction in Alzheimer's disease: Role in pathogenesis and novel therapeutic opportunities

Perez Ortiz JM, Swerdlow RH.

Br J Pharmacol. 2019 Sep;176(18):3489-3507. doi: 10.1111/bph.14585. Epub 2019 Mar 6.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias